ATE277632T1 - Impfstoffe die abgeschwächte bakterien enthalten - Google Patents

Impfstoffe die abgeschwächte bakterien enthalten

Info

Publication number
ATE277632T1
ATE277632T1 AT98959023T AT98959023T ATE277632T1 AT E277632 T1 ATE277632 T1 AT E277632T1 AT 98959023 T AT98959023 T AT 98959023T AT 98959023 T AT98959023 T AT 98959023T AT E277632 T1 ATE277632 T1 AT E277632T1
Authority
AT
Austria
Prior art keywords
strain
vaccines
attenuation
tetanus toxin
subsequent challenge
Prior art date
Application number
AT98959023T
Other languages
English (en)
Inventor
Steven N Chatfield
Mark Sydenham
Gordon Dougan
Original Assignee
Celltech Pharma Europ Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Pharma Europ Ltd filed Critical Celltech Pharma Europ Ltd
Application granted granted Critical
Publication of ATE277632T1 publication Critical patent/ATE277632T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98959023T 1997-12-11 1998-12-10 Impfstoffe die abgeschwächte bakterien enthalten ATE277632T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9726233.1A GB9726233D0 (en) 1997-12-11 1997-12-11 Vaccines containing attenuated bacteria
PCT/GB1998/003680 WO1999029342A1 (en) 1997-12-11 1998-12-10 Vaccines containing attenuated bacteria

Publications (1)

Publication Number Publication Date
ATE277632T1 true ATE277632T1 (de) 2004-10-15

Family

ID=10823476

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98959023T ATE277632T1 (de) 1997-12-11 1998-12-10 Impfstoffe die abgeschwächte bakterien enthalten

Country Status (9)

Country Link
EP (1) EP1037664B1 (de)
JP (1) JP2001525375A (de)
AT (1) ATE277632T1 (de)
AU (1) AU739191B2 (de)
CA (1) CA2313703A1 (de)
DE (1) DE69826712T2 (de)
ES (1) ES2230729T3 (de)
GB (1) GB9726233D0 (de)
WO (1) WO1999029342A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002866A (es) * 2001-09-27 2005-06-06 Gangagen Inc Composiciones bacterianas inmunogeneticas de celula completa incapacitadas.
CA2461647C (en) 2001-09-27 2012-01-24 Gangagen, Inc. Lysin-deficient bacteriophages having reduced immunogenicity
JP2008054614A (ja) * 2006-09-01 2008-03-13 Nippon Inst For Biological Science 鶏大腸菌由来弱毒変異株、鶏大腸菌対策用ワクチン、免疫方法及び鶏用ワクチンベクター
CN109517046B (zh) * 2018-11-28 2021-09-14 福建师范大学 一种基于外膜蛋白生成机制的抗菌多肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8912330D0 (en) * 1989-05-30 1989-07-12 Wellcome Found Live vaccines
JP3633933B2 (ja) * 1992-07-31 2005-03-30 アカンビス、リサーチ、リミテッド 弱毒化細菌における組換え融合タンパク質の発現

Also Published As

Publication number Publication date
JP2001525375A (ja) 2001-12-11
EP1037664A1 (de) 2000-09-27
DE69826712D1 (de) 2004-11-04
WO1999029342A1 (en) 1999-06-17
CA2313703A1 (en) 1999-06-17
AU1496099A (en) 1999-06-28
AU739191B2 (en) 2001-10-04
ES2230729T3 (es) 2005-05-01
DE69826712T2 (de) 2006-02-09
GB9726233D0 (en) 1998-02-11
EP1037664B1 (de) 2004-09-29

Similar Documents

Publication Publication Date Title
Ivins et al. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs
Jalava et al. Bacterial ghosts as vaccine candidates for veterinary applications
Tennant et al. Nontyphoidal salmonella disease: Current status of vaccine research and development
Plotkin et al. The development of vaccines: how the past led to the future
Szu et al. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high-or lower-molecular-weight Vi
Holmgren et al. An oral B subunit: whole cell vaccine against cholera
Wu et al. Protective immunity conferred by recombinant Pasteurella multocida lipoprotein E (PlpE)
Magariños et al. Influence of the capsular layer on the virulence ofPasteurella piscicidafor fish
Titball Clostridium perfringens vaccines
Olafsdottir et al. IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
Holmgren et al. New cholera vaccines
Midwinter et al. Vaccination of mice with lipopolysaccharide (LPS) and LPS-derived immuno-conjugates from Leptospira interrogans
Baba Immunogenic activity of a ribosomal fraction obtained from Pasteurella multocida
Ricci et al. Induction of protective immunity by Legionella pneumophila flagellum in an A/J mouse model
DE69826712D1 (de) Impfstoffe die abgeschwächte bakterien enthalten
Milan et al. Recombinant protein and DNA vaccines derived from hsp60 Trichophyton mentagrophytes control the clinical course of trichophytosis in bovine species and guinea‐pigs
Corbel Vaccines against bacterial zoonoses
US6582699B2 (en) Combination vaccine for enhancing immunity against brucellosis
Kharab et al. Immunogenicity of iron-regulated outer membrane proteins of Pasteurella multocida B: 2 in mice model
AU759776B2 (en) An over-expressing homologous antigen vaccine and a method of making the same
DE69028785T2 (de) Neuer impfstoff
Schwenteit et al. Construction of Aeromonas salmonicida subsp. achromogenes AsaP1‐toxoid strains and study of their ability to induce immunity in Arctic char, Salvelinus alpinus L.
Gelber et al. Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection
Weldon et al. Identification of a potentially important antigen of Pasteurella haemolytica
Gogoi et al. Comparative immunogenicity of outer membrane vesicles (OMVS) and outer membrane proteins (OMPS) of Pasteurella multocida capsular type a of pig

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties